New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Seres Therapeutics, Inc. (MCRB) vs NewcelX Ltd. (NCEL)

Seres Therapeutics, Inc. and NewcelX Ltd. are both Biotechnology companies. Seres Therapeutics, Inc. and NewcelX Ltd. are of similar size ($14.5M and $13.6M). Across the 8 metrics below, Seres Therapeutics, Inc. leads on 5 and NewcelX Ltd. on 3.

Valuation

Metric MCRB NCEL Biotechnology median
P/E n/m n/m 8.49
P/S 5.87 — 8.56
P/B 0.58 4.69 2.04
Price to free cash flow n/m n/m 23.84
EV/EBITDA 0.07 n/m 0.69
EV/Sales (2.38) — 8.00
Earnings yield (400.00%) (60.24%) (35.81%)
Free cash flow yield (510.53%) (17.29%) (25.41%)

Profitability

Metric MCRB NCEL Biotechnology median
Gross margin 100.00% — 70.18%
Operating margin (3,656.89%) — 0.00%
Net margin (2,209.55%) — 0.00%
Free cash flow margin — — 0.00%
Return on equity (144.35%) 165,532.11% (51.58%)
Return on assets (44.85%) (596.85%) (45.91%)
Return on invested capital (1,267.77%) — 0.00%

Growth

Metric MCRB NCEL Biotechnology median
Revenue growth (TTM) — — 7.20%
EPS growth (last fiscal year) — 11.18% 29.04%
Revenue growth, 5-year CAGR — — 9.54%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric MCRB NCEL Biotechnology median
Debt to equity 0.00 0.06 0.00
Current ratio 1.65 0.40 4.79
Net debt to EBITDA 0.51 0.74 1.01

Dividend

Metric MCRB NCEL Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric MCRB NCEL Biotechnology median
Market cap 13.56m 14.48m 150.57m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack